CLCF1 and cancer: Specifically, they found a time-dependent decrease in miR-30a-5p in sorafenib-treated cells and demonstrated by functional analysis the direct targeting of the pro-inflammatory cytokine CLCF1 (cardiotrophin-like cytokine factor 1) that activates the downstream PI3K/AKT pathway controlling the proliferation and metabolic reprogramming of cancer cells.